5 Undervalued Biotechnology & Medical Research Stocks for Monday, June 17
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Monday, June 17 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Grace Malone
Jenna Brashear
| Share Statistics | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $0.3 | $211.8 | 0% |
|
| Shares Out (Mil) | 0.1 | 55.4 | 1% |
|
| Institutional Ownership | 40.1% | 93.0% | 16% |
|
| Float (Mil) | 0.1 | 41.5 | 0% |
|
| Beta | 1.28 | 0.99 | 74% |
|
| Avg Daily Volume (000s) | 17 | 553 | 20% |
|
| Price Change (52-week) |
(98.9%) | 42.8% | 2% |
|
| Growth | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | 22.3% | (10.3%) | 77% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.000 | $0.000 | $0.000 | |
| Month Ago EPS | $0.000 | $0.000 | $0.000 | |
| # Rev Up | na | 1 | 1 | |
| # Rev Down | na | 0 | 0 | |
| Three Months Ago EPS | $0.000 | $0.000 | $0.000 | |
| Year/Year Chg | (100.0%) | (100.0%) | (100.0%) | |
| Financials | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $41 | na |
|
| Net Income (TTM) (Mil) | ($6) | ($44) | 32% |
|
| EPS (TTM) | ($102.505) | ($1.500) | 1% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($35) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $-0 | 42% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($4) | $147 | 3% |
|
| Valuation | BDRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.02 | 2.01 | 0% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BDRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (31.5%) | (47.4%) | 16% |
|
| ROE | (41.3%) | (53.1%) | 17% |
|
| Liabilities to Assets | 24.4% | 29.7% | 16% |
|
| F-Score | 1 | 3 | na |
|
Biodexa Pharmaceuticals Plc did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors